首页 › 非霍奇金淋巴瘤 › 犹他州 › Salt Lake City
Salt Lake City UT 非霍奇金淋巴瘤临床试验
13项针对 非霍奇金淋巴瘤的研究正在 Salt Lake City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
招募中1/2 期
- Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Intermountain Healthcare, Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Intermountain Healthcare, Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Intermountain Healthcare, Salt Lake City
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Utah, Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
招募中观察性研究
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
招募中观察性研究
- University of Utah Hospital, Salt Lake City
其他城市的 非霍奇金淋巴瘤试验
- Houston, TX31 项研究
- New York City, NY31 项研究
- Boston, MA26 项研究
- Nashville, TN21 项研究
- Philadelphia, PA20 项研究
- Baldwin Park, CA19 项研究
- Washington, DC18 项研究
- Atlanta, GA18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI18 项研究
- Columbus, OH18 项研究
- Dallas, TX17 项研究
Salt Lake City的其他研究
- 非小细胞肺癌31 项研究
- 癌症（所有类型）27 项研究
- 乳腺癌27 项研究
- 结直肠癌22 项研究
- 肺癌21 项研究
- 黑色素瘤21 项研究
- 多发性骨髓瘤21 项研究
- 转移性癌症20 项研究
- 卵巢癌19 项研究
- 肥胖症18 项研究
- 急性髓系白血病17 项研究
- 心力衰竭17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。